摘要
背景与目的肺癌射频消融术(radiofrequency ablation,RFA)联合化疗对于晚期非小细胞肺癌(nonsmall cell lung cancer,NSCLC)近期疗效的改善具有一定的意义,但其是否可以改善晚期NSCLC患者的远期生存仍然存在争议。本研究回顾性分析了射频消融术联合化疗治疗与单纯化疗对于晚期NSCLC患者的远期疗效的差异。方法选择2012年9月-2015年12月在首都医科大学宣武医院胸外科进行肺癌射频消融术并进行化疗的Ⅲb期与Ⅳ期NSCLC患者77例作为实验组,选择同期只进行化疗未进行射频消融术的Ⅲb期与Ⅳ期NSCLC患者56例作为对照组。对两组患者进行电话随访,询问患者目前的生存情况与死亡时间。运用R3.4.1软件进行统计分析,使用"survival"程序包,用卡方检验比较两组数据基线水平,运用Cox比例风险模型处理混杂偏倚,并使用协变量均值取代法绘制经过校对的生存曲线。结果两组基线齐,实验组的1年生存率为70.74%,2年生存率为39.31%,中位生存期为22.1个月;对照组的1年生存率为54.54%,2年生存率为19.49%,中位生存期为18.1个月。组间差异有统计学意义(P<0.05)。结论对于Ⅲb期-Ⅳ期NSCLC患者,肺癌射频消融术联合化疗治疗可以显著提高患者的2年生存率。
Background and objective Radiofrequency ablation （RFA） combined with chemotherapy has a certain short-term therapeutic effect for the treatment of advanced non-small cell lung cancer （NSCLC）, but whether it can improve the long-term survival rate of patients is still controversy. This study retrospectively analyzed the difference of long-term effi- cacy between RFA combined with chemotherapy and chemotherapy alone in the treatment of patients with advanced NSCLC. Methods A total of 77 patients with stage IIIb and stage IV NSCLC who underwent radiofrequency ablation and chemo- therapy in the Department of ~horacic Surgery3 Xuanwu Hospital, Capital University of Medical Sciences from September 2009 to December 2015 were enrolled as the treatment group. Chemotherapy with no radiofrequency ablation was performed in 56 patients with stage II1＇o and stage 1V NSCLC as the control group. Two groups of patients were followed up by telephone about their living conditions. ＂Survival＂ package of R software version 3.4.1 was used for statistical analysis. Two sets of data baseline levels were tested by chi-square test. The bias was processed by Cox regression model and the survival curve was plot- ted using covariate mean substitution method. Results The first-year survival rate of the treatment group was 70.74%, the two- year survival rate was 39.31% and the median survival time was 22.1 months. The one-year survival rate was 54.54% in the control group, the two-year survival rate was 19.49%, the median survival for 18.1 months. The long-term survival rate of the treatment group was better than that of the control group （P〈0.05, OR=0.571）. Conclusion Radiofrequency ablation of lung cancer combined with chemotherapy can significantly improve the 2-year survival rate of patients with stage IIIb and stage IVNSCLC.
作者
杜淑卉
秦达
庞睿奇
张叶青
赵思琪
胡牧
支修益
Shuhui DU Da Q.IN Ruiqi PANG Yeqing ZHANG Siqi ZHAO Mu HU Xiuyi ZHI(Department of Thoracic Surgery, Xuanwu Hospital, Beijing 100053, China)
出处
《中国肺癌杂志》
CAS
CSCD
北大核心
2017年第10期675-682,共8页
Chinese Journal of Lung Cancer
基金
首都医科大学2016年本科生科研创新项目(No.XSKY2016119)资助~~
关键词
肺肿瘤
射频消融术
化疗
远期疗效
Lung neoplasms
Radiofrequency ablation
Chemotherapy
Long-term efficacy
